Dr. Maria Reig is a physician-scientist internationally recognized for her expertise in liver diseases and liver cancer. She currently holds several key positions, including Head of the Hepatic Oncology Unit at the Hospital Clinic of Barcelona since 2019, Head of the Barcelona Clinic Liver Cancer (BCLC) group at IDIBAPS, and Head of the Liver Oncology Group at CIBEREHD since 2021. She plays a crucial role in leading the BCLC generational relief, propelling research, and advancing treatment for liver cancer patients. Her visionary approach is evident in the incorporation of the "Clinical Decision-making concept" into the 2022 BCLC staging system, a globally recommended classification (Reig M 2022), that has been reviewed in 2024. This innovative concept has also been adopted by the 2023 AASLD guidance (Singal 2023), further solidifying its impact in the field. 
 

She is Chair of the International Working Group for the Liver Cancers Council at Global Liver Institute (GLI), a non-profit patient organization. Actively contributing to the advancement of liver cancer care, she is involved in various scientific associations (ILCA, EASL, AEEH, ALEH, ESMO), ensuring that the patient's voice is heard, advancements translate into tangible benefits for patients, and are integrated into medical decision-making processes.  

She leds the Spanish consensus of AEEH, AEC, SEOM, SERAM, SERVEI, and SETH involved in the HCC management She is the EASL representative of the 2023 Cholangiocarcinoma guideline ILCA-EASL and the update EASL Hepatocellular Carcinoma guideline, as well as part of the board of the three-liver cancer register led by AEEH (PMIDs: 28279536; 20036398). She has been part of the Governing Board of almost all Scientific Associations devoted to Liver Cancer: ILCA, AEEH, ERN-rareLiver, and EASL. She was Chair of the EASL Scientific Committee and a member of the Scientific Committee of the Societat Catalana de Digestologia.  She is an Associate Editor in the Journal of Hepatology (IF 27.385). As an Associate Professor at the University of Barcelona, she actively promotes young investigators through hybrid stating.  

Dr Maria Reig has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consultant or Advisory Role: AstraZeneca, Bayer, BMS, Eli Lilly, Geneos, Ipsen, Merck, Roche, Universal DX, Boston Scientific, Engitix Therapeutics

Educational Support (to the institution): Bayer, Astrazeneca, Eisai- Merck MSD, Roche, Ipsen, Lilly, Terumo, BMS, Next, Boston Scientific, Ciscar Medical, Eventy C3 LLC (Egypt)